About admin

This author has not yet filled in any details.
So far admin has created 60 blog entries.

FDA Approves First Drug for Treatment of Parkinson’s Dyskinesia

The US Food and Drug Administration (FDA) has approved amantadine extended-release capsules (Gocovri, Adamas Pharmaceuticals Inc) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, the company announced on 8/25/17.

“Gocovri’s approval is an important advancement for […]

By | August 31st, 2017|News|0 Comments

FDA Approves First Drug for cGVHD After Stem Cell Transplant

In a first, the US Food and Drug Administration (FDA) has approved a drug for use in  patients who develop the life-threatening condition of chronic graft-vs-host disease (cGVHD) after having undergone a hematopoietic stem cell transplant (HSCT). The approval was received on August 2nd, 2017. […]

By | August 30th, 2017|News|0 Comments

Artificial Sweeteners Linked to Higher BMI, Cardiometabolic Risk

A new meta-analysis and systematic review finds mixed evidence to support use of artificial sweeteners for weight loss and suggests routine consumption may be associated with long-term weight gain and an increased risk of cardiometabolic disease. Nonnutritive sweeteners, such as aspartame, sucralose and

stevioside, are widely consumed, […]

By | August 29th, 2017|News|0 Comments

FDA Approves Deflazocort (Emflaza®) To Treat Duchenne Muscular Dystrophy (DMD)

On February 9th, 2017 the U.S. Food and Drug Administration (FDA) approved Emflaza® (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza® is a corticosteroid that works […]

By | February 15th, 2017|Blog, News, Pharmacy|0 Comments

Mounting Problem of Opioid Diversion: Major Emerging Problem for Health Systems in US

PM05The fight against the diversion of opioids and other controlled substances is heating up in the nation’s health systems, according to experts at a packed session at the 2016 annual meeting of the American Society of Consultant Pharmacists (ASCP). Two major factors are providing the wake-up call […]

By | January 17th, 2017|Blog, Pharmacy|0 Comments

Pioglitazone Helps Prevent Secondary Stroke In Patients With Insulin Resistance

PM03Data from a new systematic review and meta-analysis provides evidence the pioglitazone can help prevent secondary stroke in people with abnormal glucose metabolism. Pioglitazone reduced major vascular events after ischemic stroke in a recent randomized controlled trial. The purpose of this study was to conduct a meta-analysis […]

By | January 17th, 2017|Blog, News|0 Comments

FDA approves Darzalex® for patients with previously treated multiple myeloma

pci2On November 16th, 2016 the U.S. Food and Drug Administration (FDA) granted accelerated approval for Darzalex® (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex® is the first monoclonal antibody approved for treating multiple myeloma.

Multiple myeloma is a form of […]

By | December 13th, 2016|Blog, News|0 Comments

Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth

arsenicDiabetes mellitus characterized by hyperglycemia is an increasing worldwide health problem. It is largely classified into insulin-dependent diabetes mellitus (type 1 diabetes) and noninsulin-dependent diabetes mellitus (type 2 diabetes). The type 2 diabetes (T2D) makes up more than 90% of all diabetes cases. Established risk factors for […]

By | December 7th, 2016|Blog, News|0 Comments

FDA Approves Prasterone (Intrarosa®) for Dyspareunia in Postmenopausal Women

pci2 On November 17th, 2016 the U.S. Food and Drug Administration (FDA) approved Intrarosa® (prasterone) manufactured by Quebec-based Endoceutics treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Intrarosa® is the first FDA […]

By | December 5th, 2016|Blog, News|0 Comments

Direct Switching From TNF Rheumatoid Arthritis (RA) Drugs Shows Beneficial Effect in Non-Responsive Patients

pci3Rheumatoid arthritis (RA), the most common autoimmune disease, is characterized by persistent synovitis and systemic inflammation. Genetic predisposition as well as autoantibodies and environmental factors, such as smoking, are associated with an increased risk of RA. Traditionally RA has been treated with disease modifying anti-rheumatic drugs (DMARDs) […]

By | November 21st, 2016|Blog, Pharmacy|0 Comments